{"entity":{"id":"nct07299747","kind":"trial","name":"Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of VBC103 in advanced solid tumours, run by VelaVigo Bio Inc, now recruiting.","summary":"Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors. ClinicalTrials.gov record last updated 2026-04-22: recruiting. Enrollment is planned at 255 participants. Primary completion is estimated at 2027-12-01. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: VBC103. Registered primary measures: Incidence of dose-limiting toxicities (DLT) as defined in the protocol; Incidence of Serious Adverse Events.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT07299747","url":"https://clinicaltrials.gov/study/NCT07299747"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["adc"],"targets":["trop2","nectin4"],"drugs":[],"companies":["velavigo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-04-22: recruiting. Enrollment is planned at 255 participants. Primary completion is estimated at 2027-12-01. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT07299747","phase":"1/2","setting":"Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors","sponsor":"VelaVigo Bio Inc","participation":[{"nct":"NCT07299747","source":"https://clinicaltrials.gov/study/NCT07299747","fetchedAt":"2026-10-07T16:55:39.854Z","studySha256":"871f5b3ed9e53026e9dad6f4c2703653bc64ef4dc66e32d517ae5c8c6137a8de","overallStatus":"RECRUITING","lastUpdatePosted":"2026-04-22","leadSponsor":"VelaVigo Bio Inc","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":255,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2025-12-04","startedType":"actual","enrolled":255,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07299747/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"nectin4","kind":"target","name":"Nectin-4","route":"/targets/nectin4/"},{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"company":[{"id":"velavigo","kind":"company","name":"VelaVigo","route":"/companies/velavigo/"}],"drug":[{"id":"vbc103","kind":"drug","name":"VBC103","route":"/drugs/vbc103/"}]}}